A Aralex Aachen research explorer

Julie Nicole Meade Sign in to save

OpenAlex profile details not fetched

–

Citations

–

h-index

–

i10-index

–

Works (all)

0

Aachen papers

Departments & institutes in Aachen

No department could be parsed from this author's affiliation strings.

Affiliations exactly as printed on papers (2)

4× Deciphera Pharmaceuticals, LLC, Waltham, MA;
2× Clinical Development, Deciphera Pharmaceuticals, LLC, Waltham, MA, USA

Papers 6 stored

All · Aachen affiliation only

INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib
2022 Journal of Clinical Oncology conference-abstract Medicine Gastrointestinal Tumor Research and Treatment

18

citations
1540P Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study
2021 Annals of Oncology article Medicine Gastrointestinal Tumor Research and Treatment Open access

18

citations
Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study.
2021 Journal of Clinical Oncology conference-abstract Medicine Gastrointestinal Tumor Research and Treatment

0

citations
1622MO Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
2020 Annals of Oncology article Medicine Gastrointestinal Tumor Research and Treatment Open access

1

citations
Quality of life (QoL) and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.
2020 Journal of Clinical Oncology conference-abstract Medicine Gastrointestinal Tumor Research and Treatment

10

citations
Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.
2020 Journal of Clinical Oncology conference-abstract Medicine Gastrointestinal Tumor Research and Treatment

4

citations

6 results